Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4110186 | 0.86 | NQO1 (0.34) | CYP1A2 | |
| SCHEMBL2286007 | 0.79 | PDE10A (0.39) | CYP1A2 | |
| SCHEMBL2286829 | 0.78 | BACE1 (0.32) | — | |
| SCHEMBL4110510 | 0.78 | DHFR (0.33) | — | |
| Tirasemtiv SCHEMBL977536 | 0.76 | CYP1A2 (0.54) | CYP1A2 | |
| SCHEMBL4120161 | 0.75 | PDE10A (0.44) | — | |
| SCHEMBL2289587 | 0.75 | NCF1 (0.33) | — | |
| SCHEMBL2289581 | 0.74 | — | — | |
| SCHEMBL2292642 | 0.73 | DHFR (0.31) | — | |
| SCHEMBL2287783 | 0.73 | DHFR (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7998976-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-16 | — | — | US | claimed |
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-10-01 | — | — | US | claimed |
| US-7998976-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998976-B2 | Certain chemical entities, compositions and methods | CYTOKINETICS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-10-01 | — | — | US | disclosed |
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | CYTOKINETICS, INCORPORATED | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247571-A1 | Certain Chemical Entities, Compositions and Methods | TNNC1, TNNI3, TNNT2 | CYP1A2 3794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.